1-1 of 1
Janet Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b Multi-Center Study of the FLT3 Inhibitor Gilteritinib in Combination with the IDH1 Inhibitor Ivosidenib or the IDH2 Inhibitor Enasidenib for Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring FLT3/IDH1 or FLT3/IDH2 Mutations

Eytan M. Stein, Andriy Derkach, Gabrielle Melamed, Alana Block, Janet Kim, Gergana Georgieva, Vanessa Thompson, Ross L Levine, Andrew M. Intlekofer, Omar Abdel-Wahab, Martin S. Tallman
Journal: Blood
Blood (2023) 142 (Supplement 1): 5945.
https://doi.org/10.1182/blood-2023-190801
Published: 2023